Spectrila 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0034/G 
This was an application for a group of variations. 
20/06/2023 
n/a 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.g.4.b - Changes to an approved change 
management protocol - Minor changes that do not 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
change the strategy defined in the protocol 
II/0032/G 
This was an application for a group of variations. 
09/03/2023 
SmPC and PL 
SmPC new text 
C.I.4: Update of sections 4.4 and 4.6 of the SmPC in 
order to include the recommendations from the SWP 
regarding genotoxic medicinal products and 
contraception duration period; the Package Leaflet is 
updated accordingly. In addition, the MAH took the 
opportunity to introduce minor editorial changes to 
the PI. 
C.I.6.b: Deletion of the indication lymphoblastic 
lymphoma (LBL) in section 5.3 of the SmPC, as 
Spectrila is not approved for LBL. 
C.I.6.b - Change(s) to therapeutic indication(s) - 
Deletion of a therapeutic indication 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0033/G 
This was an application for a group of variations. 
08/12/2022 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.III.2.z - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Other 
variation 
For more information, please refer to the Summary of 
Product Characteristics. 
Page 2/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0029 
B.I.e.2 - Introduction of a post approval change 
08/12/2022 
n/a 
management protocol related to the AS 
II/0031 
B.II.g.2 - Introduction of a post approval change 
01/09/2022 
n/a 
management protocol related to the finished product 
IB/0030 
C.I.11.z - Introduction of, or change(s) to, the 
26/04/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
II/0026 
B.I.b.2.d - Change in test procedure for AS or 
24/03/2022 
n/a 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
IB/0028 
B.II.b.3.a - Change in the manufacturing process of 
06/01/2022 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IA/0027 
A.5.b - Administrative change - Change in the name 
19/11/2021 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
II/0025 
B.I.b.2.d - Change in test procedure for AS or 
02/09/2021 
n/a 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
Page 3/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
biological AS 
PSUSA/10445
Periodic Safety Update EU Single assessment - 
02/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202101 
asparaginase (centrally authorised product) 
IA/0023/G 
This was an application for a group of variations. 
07/01/2021 
n/a 
B.III.2.a.2 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - Excipient/AS starting material 
A.7 - Administrative change - Deletion of 
manufacturing sites 
II/0021/G 
This was an application for a group of variations. 
10/12/2020 
n/a 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.b - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol 
Page 4/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product and any of the test methods at the site is a 
biol/immunol method 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
IA/0022 
A.4 - Administrative change - Change in the name 
30/11/2020 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
R/0018 
Renewal of the marketing authorisation. 
23/07/2020 
24/09/2020 
SmPC, 
Labelling and 
PL 
PSUSA/10445
Periodic Safety Update EU Single assessment - 
04/09/2020 
n/a 
PRAC Recommendation - maintenance 
/202001 
asparaginase (centrally authorised product) 
IB/0020 
B.II.b.2.a - Change to importer, batch release 
15/07/2020 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
II/0017 
Update of the Risk Management Plan (version 12) for 
14/05/2020 
n/a 
Spectrila in accordance with GVP Module V Rev 2 
including the implementation of the new RMP 
template and the new definition of safety concerns. 
The QPPV and the Milestones / Timelines for the 
clinical study MC-Spectrila.1/ALL were updated in 
accordance to the newly applied DLP for this Risk 
Management Plan. 
Page 5/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
II/0015/G 
This was an application for a group of variations. 
05/03/2020 
n/a 
B.II.b.5.a - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
B.II.b.5.b - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Addition of a new test(s) and limits 
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.e.1.z - Change in immediate packaging of the 
finished product - Other variation 
Page 6/9 
 
 
 
 
 
 
 
 
 
 
 
IA/0016 
A.4 - Administrative change - Change in the name 
18/12/2019 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/10445
Periodic Safety Update EU Single assessment - 
11/07/2019 
n/a 
PRAC Recommendation - maintenance 
/201901 
asparaginase (centrally authorised product) 
IB/0014 
B.I.a.1.f - Change in the manufacturer of AS or of a 
05/06/2019 
n/a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
PSUSA/10445
Periodic Safety Update EU Single assessment - 
28/02/2019 
26/04/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201807 
asparaginase (centrally authorised product) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10445/201807. 
IB/0012/G 
This was an application for a group of variations. 
04/01/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
Page 7/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
IB/0009 
B.II.b.5.z - Change to in-process tests or limits 
13/08/2018 
n/a 
applied during the manufacture of the finished 
product - Other variation 
PSUSA/10445
Periodic Safety Update EU Single assessment - 
12/07/2018 
n/a 
PRAC Recommendation - maintenance 
/201801 
asparaginase (centrally authorised product) 
IB/0008 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
18/06/2018 
26/04/2019 
SmPC and 
life of the finished product - As packaged for sale 
Labelling 
(supported by real time data) 
PSUSA/10445
Periodic Safety Update EU Single assessment - 
08/02/2018 
n/a 
PRAC Recommendation - maintenance 
/201707 
asparaginase (centrally authorised product) 
IA/0006 
A.5.b - Administrative change - Change in the name 
19/12/2017 
n/a 
and/or address of a manufacturer/importer of the 
Page 8/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
PSUSA/10445
Periodic Safety Update EU Single assessment - 
01/09/2017 
n/a 
PRAC Recommendation - maintenance 
/201701 
asparaginase (centrally authorised product) 
IB/0003 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
20/07/2017 
29/06/2018 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
PSUSA/10445
Periodic Safety Update EU Single assessment - 
09/02/2017 
n/a 
PRAC Recommendation - maintenance 
/201607 
asparaginase (centrally authorised product) 
Page 9/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
